date,title,source
Oct-22-18,Strongbridge Biopharma plc Presents Detailed Initial Results from Pivotal Phase 3 SONICS Study of RECORLEV (levoketoconazole) for the Treatment of Endogenous Cushings Syndrome at the 18th Annual Congress of the European NeuroEndocrine Association,GlobeNewswire
